DTPA双酰胺杂环钆(Ⅲ)配合物的合成、表征与弛豫效能

通过二乙三胺五乙酸(DTPA)酸酐与一种新型杂环化合物的酰化反应,得到了双酰胺共价键链接、杂环化合物修饰的DTPA配体。再与GdCl₃·6H₂O反应得到相应的顺磁性钆(Ⅲ)配合物。通过元素分析、FTIR、1H NMR等手段表征了配体和金属配合物的结构,进而测定了配合物的纵向弛豫率(R₁)。结果表明,配合物分子稳定性很好,且在同等含钆量条件下,这种新型钆(Ⅲ)金属配合物的R₁(5.12 mmol·L-1·s-1)高于临床应用的磁共振成像对比剂Gd-DTPA(3.64 mmol·L-1·s-1)。     

L-赖氨酸长链烷基酯双DTPA酰胺钆(Ⅲ)配合物的合成、表征与弛豫效能

通过二乙三胺五乙酸单环酸酐(DTPA-MA)分别与L-赖氨酸的十八酯、十六酯、十四酯和十二酯的双酰化反应, 制得四种含有双DTPA螯合单元的新型配体. 它们与GdCl3·6H2O配合得到相应的双核钆(Ⅲ)配合物. 表征了配体和配合物的结构, 测试了配合物的纵向弛豫效能(R1). 结果表明: 这四种新钆配合物的R1都高于Gd-DTPA.     

Evaluation of two new gadolinium chelates as contrast agents for MRI

Two new gadolinium chelates were investigated for potential use as tissue-specific contrast agents for magnetic resonance imaging. In vitro measurements of stability constants, octanol/water partition coefficients and relaxation times in solutions of water and human serum albumin (HSA) were performed with each new chelate and compared with gadolinium-diethylenetriamine pentaacetic acid, Gd(DTPA). Biodistribution studies and magnetic resonance imaging in rats were used to evaluate the new chelates in vivo. The stability constants (log K) of gadolinium-N,N″-bis(3-hydroxy-6-methyl-2-pyridylmethyl)diethylenetriamine-N,N′,N″-triacetic acid, Gd(DTTA-HP), and gadolinium-1,7-13-triaza-4,10-16-trioxacyclooctadecane-N,N′,N″-triacetic acid, Gd(TTCT), were determined to be 23.65 and 18.07, respectively. These can be compared to a literature value of 22.46 for Gd(DTPA). Octanol/water partition coefficients for both complexes showed they were more lipophilic than Gd(DTPA). Gd(DTTA-HP) exhibited a smaller relaxivity in water but a larger relaxivity in 4% HSA than Gd(DTPA). Gd(TTCT) exhibited a lower relaxivity than Gd(DTPA) in both water and 4% HSA. Both complexes showed similar biodistributions to Gd(DTPA) no carrier-added concentrations. Gd(DTTA-HP) had a greater percent change in signal intensity than Gd(DTPA) on T₁-weighted spin-echo images in the heart, liver, and kidney. Percent change in signal intensity for Gd(TTCT) was lower than Gd(DTPA) in heart, liver, and kidney.     

紫外差光谱测定Gd(Ⅲ), Yb(Ⅲ)与HBED配合物的条件稳定常数

在0.01 mol·L-1 N-2-羟乙基哌嗪-N'-2-乙磺酸(Hepes), pH 7.4, 室温条件下, 应用紫外差光谱滴定观察了Gd(Ⅲ), Yb(Ⅲ)与N, N'-二(2-羟苄基)乙二胺-N, N'-二乙酸(HBED)的结合. 结果表明 Gd(Ⅲ), Yb(Ⅲ)与HBED均形成1∶1的配合物, 其紫外差光谱均于237和291 nm处出现吸收峰, 在237 nm处配合物Gd-HBED与Yb-HBED的摩尔吸光系数分别为 ΔεGd=(22.52±0.20)×103 cm-1·mol-1·L, ΔεYb=(27.15±0.11)×103 cm-1·mol-1·L; 配合物Gd-HBED与Yb-HBED的条件稳定常数分别为 lgKGd-HBED=13.56±0.28, lgKYb-HBED=16.06±0.03, 符合线性自由能关系.     

Reaction of gadolinium chelates with endogenously available ions

The extent of reaction of 153Gd-radiolabeled Gd(L) chelates with 25 mM CO23- (25 mF), PO34-, Zn2+ and Cu2+ at pH 7 was determined for L = EDTA, DTPA, DOTA, HP-DO3A, and DO3A. Gd(EDTA)- and Gd(DTPA)2- reacted (greater than 20% in 10 min) with Cu2+ and Zn2+ in the presence of PO34-. These double replacement reactions yielded precipitated GdPO4 and chelated Cu(L). Gd(HP-DO3A), Gd(DO3A) and Gd(DOTA)- were inert to reaction with all four ions at room temperature (less than or equal to 1% reaction detected). The thermodynamic binding constants of the ligands for Gd3+ and Cu2+ were found to be equal (10(20) M-1) for DO3A, while DOTA and HP-DO3A favored Gd3+ over Cu2+ by greater than or equal to 10(2) M-1. The low order of reactivity of Gd(DOTA)- and Gd(HP-DO3A) was anticipated by the binding constants, but the lack of reactivity of Gd(DO3A) is attributed to kinetic inertia. This latter property, desirable in MRI contrast agents, is promoted by the conformational stability of the tetraazacyclododecane macrocycle, which forms the backbone of the ligand. It is concluded that this class of chelates is exceptionally inert in solutions of endogenously available ions, and that thermodynamics alone is an insufficient predictor of the reactivity of the highly inert Gd complexes based on the tetraazamacrocycle.     

Investigation of sandwiched gadolinium (III) complexes with tungstosilicates as potential MRI contrast agents

Two gadolinium-sandwiched complexes with tungstosilicates, K(13)[Gd(SiW(11)O(39))(2)] (Gd(SiW(11))(2)) and K(11)H(6)[Gd(3)O(3)(SiW(9)O(34))(2)] (Gd(3)(SiW(9))(2)), have been investigated by in vitro and in vivo experiments as potential contrast agents for magnetic resonance imaging (MRI). T(1)-relaxivity of Gd(SiW(11))(2)was 6.59 mM(-1).s(-1) in aqueous solution and 6.85 mM(-1).s(-1) in 0.725 mmol.L(-1) bovine serum albumin solution at 25 degrees C and 9.39 T, respectively. The corresponding T(1)-relaxivity of Gd(3)(SiW(9))(2) was 12.6 and 19.3 mM(-1).s(-1) per Gd, respectively. MRI for Sprague-Dawley rats showed longer and more remarkable enhancement in rat liver after i.v. injection of these two complexes: 39.4 +/- 3.9% and 57.4 +/- 11.6% within the first 30 min after injection, 31.2 +/- 2.6% and 39.9 +/- 7.6% in the next 60 min for Gd(SiW(11))(2) and Gd(3)(SiW(9))(2) at doses of 0.081 and 0.084 mmol Gd/kg, respectively. Our preliminary in vitro and in vivo study indicates that Gd(SiW(11))(2) and Gd(3)(SiW(9))(2) are favorable candidates for hepatic contrast agents for MRI. However, the two complexes exhibit higher acute toxicity and need to be modified and studied further before clinical use.     

Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: early phase II study in brain tumors and dual dynamic contrast-enhanced imaging

PURPOSE: A newly developed contrast material, CH3-DTPA-Gd (NMS60), a trimer containing 3 Gd(3+) atoms per molecule, has been shown to offer greater enhancement and longer vascular retention than gadopentetate dimeglumine (Gd-DTPA) in animals. We report on our early phase II study on NMS60 in brain tumor patients together with supplementary investigations. METHODS AND MATERIALS: The longitudinal relaxation rate (R(1)=1/T(1)) and the transverse relaxation rate (R(2)*=1/T(2)*) of NMS60 and Gd-DTPA were determined at 20 degrees C in water at 1.5 T. An NMS60 dose of 0.1 or 0.2 mmol (Gd)/kg was randomly assigned and administered to 10 patients (five women, five men; mean age: 49 years) with brain tumors. Safety and contrast-enhancing ability of NMS60 were evaluated. Dual dynamic contrast-enhanced T(1) and R(2)* studies (DUCE imaging) were also carried out in two patients. RESULTS: Regarding the relaxivity per Gd, R(1) and R(2)* of NMS60 were 9.5 and 11.0 (mmol/L x s)(-1), respectively, compared to 4.8 and 7.2 (mmol/L x s)(-1) for Gd-DTPA. Although a transient slight increase of alanine aminotransferase was observed in one case, no other adverse reactions were observed after administration of NMS60. Contrast enhancement by NMS60 was excellent at both concentrations, and when tumor detectability was assessed with a five-point scale, the diagnostic usefulness was 4 or higher in all cases. In DUCE imaging, NMS60 appeared to show high signal intensity, when compared with the data obtained separately for Gd-DTPA. CONCLUSION: NMS60 had a high contrasting effect and little toxicity, and is expected to be clinically useful.     

Gated magnetic resonance imaging of acute myocardial ischemia in dogs: application of multiecho techniques and contrast enhancement with GD DTPA

ECG gated magnetic resonance images were obtained in six canines prior to and immediately following occlusion of either the LAD or circumflex coronary artery using a surgically placed snare. Multiecho and single-echo acquisition techniques were utilized 0.25 mmol/kg Gd DTPA was injected as an IV bolus 1 hr following coronary artery ligation. In two animals, the region of ischemic myocardium was clearly visualized on multiecho technique without the use of intravenous contrast. The ischemic zone could be best identified on images with a long TE of 120 msec. Contrast enhancement with Gd DTPA enabled visualization of the ischemic myocardium in all six canines. Administration of Gd DTPA, a perfusion agent, improved both detectability and definition of the myocardial lesions.     

Syntheses, Characterization and Fluorescent Properties of Six Novel Lanthanide Complexes with N,N-diphenyl-2-(quinolin-8-yloxy)acetamide

Six novel complexes of lanthanide nitrates (Ln = La, Sm, Eu, Gd, Tb, Dy) with a amide type ligand, N-methyl-N-phenyl-2-(quinolin-8-yloxy)acetamide (L) have been prepared and characterized by elemental analysis, conductivity measurements, IR and ¹H NMR spectra. The fluorescence properties of the complexes and the triplet state energy of the ligand were studied in detail. The result indicates that, the triplet state energy level of the ligand matches better to the resonance level of Eu(III) than Tb(III). In addition, the fluorescence intensities of the Eu(III) complex in different solutions(tetrahydrofuran, acetone and acetonitrile) are stronger than that in solid state. This is probably due to the solvate effect and the stoichiometry change of ligand with Eu(III) ion in solutions.     

氨基酸共聚物修饰的生物相容性MRI造影剂

通过天门冬氨酸(Asp)、异亮氨酸(Ile)热缩聚反应,制备了天门冬氨酸-异亮氨酸共聚物(AI),通过乙二胺(EDA)胺化,并与1,4,7,10-四氮杂环十二烷-1,4,7,10-四羧酸(DOTA)连接,再与钆离子(Gd3+)络合,合成了生物相容性大分子磁共振成像(MRI)造影剂——AI-EDA-DOTA-Gd.运用红外光谱(IR)、核磁共振(NMR)、电感耦合等离子谱(ICP)等方法对其进行结构表征,并通过弛豫性能、溶血性质、急性毒性及动物体内成像对其进行综合评价.体外弛豫结果表明,AI-EDA-DOTA-Gd的纵向弛豫效率(r_1=12.6mmol~(–1)×L×s~(–1))是商用造影剂Gd-DOTA(r_1=5.8 mmol~(–1)×L×s~(–1))的2.2倍.动物组织生理切片和溶血性实验结果说明其具有良好的生物相容性和较低的毒性.动物体内成像结果显示,AI-EDA-DOTA-Gd的最佳成像时间为30~70 min,注射AI-EDA-DOTA-Gd后的肝脏组织信号相比于未注射造影剂时增强了约(55.1±5.7)%.     

The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption

To provide contrast enhancement in magnetic resonance imaging, a new class of compounds has been developed, the paramagnetic metal ion chelates. Gadolinium (Gd) DTPA, a prototype of this class, shows a sufficiently high in vivo stability and low toxicity for use in initial clinical trials. This type of agent, designed for rapid clearance by glomerular filtration, allows the assessment on MRI of renal function, alterations in tissue perfusion, myocardial ischemia, and perhaps most significantly disruption of the blood-brain barrier (BBB). Research at Vanderbilt has demonstrated these applications, with particular emphasis in three areas. Tissue perfusion changes, such as those produced by ligation of the arterial blood supply to portions of the spleen and kidney, cannot easily be detected on unenhanced MRI. These acute tissue infarcts can be readily identified following the administration of Gd DTPA. The question of field strength dependence of Gd DTPA has been addressed by experimentation at 0.15, 0.5, and 1.5 tesla. Furthermore, the ability to detect an alteration of the BBB, when present without associated edema, has been demonstrated with the application of control enhancement. The use of contrast agents in MRI will enhance both the sensitivity and specificity of magnetic resonance imaging.     

草酸根桥联的钆-铬六核双金属配合物的红外光谱研究

通过２,２′－联吡啶取代的草酸铬化合物和氯化钆在水溶液中反应合成了草酸根桥联的钆－铬六核双金属配合物的晶体。本文着重讨论该配合物的红外光谱。．     

重稀土高氯酸盐甲基苯甲酰甲基亚砜配合物的合成及Tb3+的发光

合成了重稀土高氯酸盐甲基苯甲酰甲基亚砜配合物RE(ClO4)3·L5·C2H5OH(RE=Gd,Tb,Dy,Tm,Yb;L=C6H5COCH2SOCH3).经元素分析、稀土络合滴定、摩尔电导及热重分析确定了配合物的组成,测定了配体及配合物的IR谱、1H NMR及铽配合物的磷光光谱、荧光激发和发射光谱,根据荧光发射光谱数据计算了铽配合物的各能级值.     

铽与两种不同结构羧酸配合物的低温固相合成及发光性质研究

以两种不同结构的羧酸苯乙酸和苯基羟基乙酸与氯化铽为原料,采用低温固相反应合成了两种羧酸铽配合物。经元素分析、稀土络合滴定、摩尔电导确定了配合物的组成为： Tb(L₁)₃·H₂O,Tb(L₂)₃·4H₂O(L₁= C₆H₅ CH COO- ,L₂=C₆H₅CH(OH)COO-)。测定了配体及配合物的IR谱、1H NMR及配体的磷光光谱和铽配合物荧光激发和发射光谱。根据磷光发射光谱数据计算了配体的三重态能级值。比较两个配合物的荧光发射主峰5D₄→7F₅强度： 苯基羟基乙酸铽为苯乙酸铽的5倍。由此可见在配体亚甲基上引入拉电子基团羟基,将会扩大共轭体系π电子的离域范围,提高能量传递效率,提高稀土离子的发光强度。     

一种肝脏类生物相容性氨基酸共聚物磁共振成像造影剂

一种新型的以天门冬氨酸-苯丙氨酸共聚物为载体的大分子生物相容性材料(AP-EDA-DOTA-Gd)被制备出来作为磁共振成像造影剂．首先合成了天门冬氨酸-苯丙
氨酸共聚物,之后利用乙二胺将1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)连接到共聚物上,最后将钆离子通过配位的作用方式连接到DOTA 上,最终得到大分子AP-EDA-DOTA-Gd．体外溶血性试验表明AP-EDA-DOTA-Gd 具有较好的血液相容性．在pH = 5.5 的组织蛋白酶B 的磷酸缓冲液中,AP-EDA-DOTA-Gd 能够降解．APEDA-DOTA-Gd 的体外弛豫效率(15.95 mmol^–1?L?s^–1)为目前临床应用的Gd-DOTA (5.59mmol^–1?L?s^–1)的2.9 倍．大鼠肝脏成像实验结果表明,AP-EDA-DOTA-Gd 对于肝组织的成像增强对比度为63.5±6.1%远高于Gd-DOTA (24.2±2.9%)．     

The gadolinium complexes with polyoxometalates as potential MRI contrast agents

The two gadolinium (Gd) polyoxometalates, K(15)[Gd(BW(11)O(39))(2)] [Gd(BW(11))(2)] and K(17)[Gd(CuW(11)O(39))(2)] [Gd(CuW(11))(2)] have been evaluated by in vivo and in vitro experiments as the candidates of potential tissue-specific magnetic resonance imaging (MRI) contrast agents. T(1) relaxivities of 17.12 mM(-1) x s(-1) for Gd(BW(11))(2) and 19.95 mM(-1) x s(-1) for Gd(CuW(11))(2) (400 MHz, 25 degrees C) were much higher than that of the commercial MRI contrast agent (GdDTPA). Their relaxivities in bovine serum albumin and human serum transferrin solutions were also reported. After administration of Gd(BW(11))(2) and Gd(CuW(11))(2) to Wistar rats, MRI showed longer and remarkable enhancement in rat liver and favorable renal excretion capability. The signal intensity increased by 37.63+/-3.45% for the liver during the whole imaging period (100 min) and by 61.47+/-10.03% for kidney within 5-40 min after injection at 40+/-1-micromol x kg(-1) dose for Gd(CuW(11))(2), and Gd(BW(11))(2) induced 50.44+/-3.51% enhancement in the liver in 5-50-min range and 61.47+/-10.03% enhancement for kidney within 5-40 min after injection at 39+/-4 micromol x kg(-1) dose. In vitro and in vivo study showed that Gd(BW(11))(2) and Gd(CuW(11))(2) are favorable candidates as tissue-specific contrast agents for MRI.     

配合物La（C5O3H3）3·C12H8N2·H2O的合成和表征

本以α－呋喃甲酸（Ｃ５Ｏ３Ｈ４）和邻菲罗啉（Ｃ１２Ｈ８Ｎ２）为配体,在乙醇８溶剂中与硝酸镧反应,合成了与稀土离子Ｌａ（Ⅲ）的三元混配配合物。经元素分析确定其配合物的组成为Ｌａ（Ｃ５Ｏ３Ｈ３）·Ｃ１２Ｈ８Ｎ２·Ｈ２Ｏ,同时还通过了ＩＲ、＾１ＨＮＭＲ、ＵＶ、ＴＧ－ＤＴＡ等谱光的测试与分析,表征了配合物的组成结构和性质。ＩＲ、＾１ＨＮＭＲ和ＵＶ谱的分析结果表明配体羧酸是以脱质子的酸根形式与中心稀土离子     

一种1,4-噻嗪酰胺类FKBPs配体的波谱学数据解析

（3R）-4-[（4-甲基苯磺酰基）]-1,4-噻嗪-3-酰基-[（2R）-2-氨基-4-甲基]-戊酸异丙酯（代号：HD5-6）,是一个拥有完全自主知识产权的FK506结合蛋白家族（FKBPs）配体,具有显著的促神经再生作用,有望在临床实现对神经退行性疾病和肌萎缩侧索硬化、脑卒中的有效治疗.本文采用多种核磁共振（NMR）技术,包括¹H NMR、¹³C NMR、DEPT、1D NOESY、¹H-¹H COSY、¹H-¹³C HSQC和¹H-¹³C HMBC等,并结合质谱（MS）、紫外光谱（UV）和红外光谱（IR）等方法对此化合物进行解析,对其¹H和¹³C NMR谱峰进行全归属,通过多种谱学技术确证了该化合物的化学结构.     

2-[2-(5-溴喹啉)-偶氮]-5-二乙氨基苯酚固相萃取光度法测定环境样品中镉的研究

合成了新试剂2-[2-(5-溴喹啉)-偶氮]-5-二乙氨基苯酚(5-Br-QADEAP),试剂结构通过元素分析,红外光谱和核磁共振氢谱鉴定。研究了5-Br-QADEAP与镉的显色反应,在pH 8.0的硼酸-氢氧化钠缓冲介质中,Triton X-100存在下,5-Br-QADEAP与镉反应生成2∶1稳定络合物,体系最大吸收波长λ_max=595 nm,摩尔吸光系数ε=1.60×105 L·mol-1·cm-1,样品中的镉用强阴离子交换固相萃取柱固相萃取预分离和富集后用该方法测定,方法相对标准偏差在2.5%～3.2%之间,标准回收率在96%～105%,结果令人满意。     

Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats

Rat plasma distribution data obtained following IV administration of 99mTc(DTPA) alone or after co-administration of 99mTc(DTPA) and 153Gd-labeled Gd(DTPA)2- at 0.001, 0.1, and 1.0 mmol Gd/kg were evaluated using compartmental modeling techniques. A three-compartment open model was found to fit the data significantly better (P less than 0.01) than a two- or four-compartment open model. This model incorporates and links the plasma and urine data and includes a delay to account for the transit time through the kidneys/ureters. The two nonplasma compartments of the model were assumed to be related to rapidly and slowly equilibrating tissues. Tc(DTPA) and Gd(DTPA)2- had nearly identical pharmacokinetic profiles in plasma and the rate constants were essentially the same. No significant dose dependent pharmacokinetic differences were found for the range of Gd(DTPA)2- doses tested. Simulations of the proposed three-compartment model were used to generate concentration-time curves for each of the three compartments.